CD Genomics provides accurate Circulating Tumor DNA Sequencing services using next-generation sequencing (NGS) technology.
Cell-free, circulating tumor DNA (ctDNA) can act as a noninvasive cancer biomarker, offering a potential alternative to invasive tissue biopsies. Today, researchers are investigating the use of ctDNA as a biomarker for detecting the presence of tumors in various cancer types. In the future, ctDNA could potentially serve as a noninvasive approach for real-time monitoring of treatment response and identifying candidates for therapy.
Next-generation sequencing (NGS) offers the sensitivity and specificity needed to detect low levels of ctDNA in the bloodstream. In addition to targeting a single gene or a subset of genes, NGS can also identify genome-wide tumor-derived alterations in ctDNA.
CD Genomics provides high- and low-throughput ctDNA sequencing services. Using state-of-the-art reagents, software and facilities, we provide a full suite of ctDNA sequencing services with the highest level of quality assurance. Our ctDNA sequencing service using the next-generation sequencing technology provides tests that are more robust, accurate and reliable in resolving allele-level differences in ctDNA of blood.
|•||Very low input DNA requirement|
|•||Sequencing compatibility with short DNA fragments|
|•||Comprehensive assay: One assay provides high-resolution sequencing, replacing multiple assays |
GenSeq Comprehensive TP53 Panel
GenSeq Comprehensive Oncology Panel
|•||Unambiguous results: Deeper sequencing with amplicons and paired-end reads enables phasing of TP53 or more oncology-related genes for more accurate, high-resolution typing.|
|•||Sample-to-report solution: Complete workflow includes ctDNA separation, library prep, sequencing, data analysis, and reporting|
• Raw data as FASTQ files via hard drive
• Mutation discovery report
The service is offered for Research use only. Not for use in diagnostic procedures.